drugset / Trial / NCT01031719

Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors

NCT01031719 ↗

Phase 3 Completed 59 enrolled Chiltern Pesquisa Clinica Ltda
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of A(H1N1) inactivated influenza virus vaccine in subjects with Solid Invasive Tumors and to compare safety and immunogenicity data with a contemporaneously enrolled control group of age-comparable, healthy subjects. Because certain individuals may be hypo-responsive to influenza vaccination, additional studies with high-risk groups are warranted in order to determine the optimal vaccine formulation and dosing schedule for prevention of novel H1N1 virus infection.

Timeline

Start
2010-08
Primary completion
2011-09
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject adjuvanted A(H1N1) influenza vaccine Vaccine 7.5 ug —
Subject non-adjuvanted A(H1N1) influenza vaccine Vaccine 15 ug —

Indications